|
Cancer
Cell’s Capture Enhanced by NaturalNano’s Halloysite Natural Tubes
ROCHESTER, N.Y., October 8, 2009 -- NaturalNano, Inc. (OTCBB:NNAN
- News;
Frankfurt:N3N -
News)
Acting CEO and President James Wemett announced today that the series of
Cornell’s feasibility studies using Halloysite Natural Tubes has been very
successful. This has been initiated under the direction of Professor Michael
King, Ph.D. of the Department of Biomedical Engineering at Cornell University
in Ithaca, New York and in co-operation with
CellTraffix Inc.
Dr King states, “NaturalNano's proprietary Halloysite nanotubes
have enhanced the cell adhesion of circulating cancer cells to reactive
surfaces and are found to be non toxic to the cells” The Halloysite
significantly decreased the rolling velocity and increased the number of cancer
cells captured using these Natural Tubes."
Wemett said, "These results are very exciting to NaturalNano.
We are continuing to work with Cornell and the Research Lab of Dr. King."
"The success of the
combination of Halloysite nanotubes and
Dr. King’s technology significantly advances our progress in developing
our device used commercially to isolate stem or certain cancer cells,"
said Thomas Fitzgerald, CEO of CellTraffix, which is commercializing the
research done by Dr. King and his team.
About NaturalNano,
Inc.
NaturalNano, Inc. (OTCBB:NNAN - News; Frankfurt:N3N - News) is a materials science company focused
on developing and commercializing advanced nanocomposites. Based in Rochester, NY,
the Company is focused on additive technologies and processes, including its
proprietary Pleximer polymer additive, that add value to industrial polymers,
plastics and composites, as well as consumer and industrial products.
NaturalNano holds and licenses over 25 patents and applications, as well as
proprietary know-how for extraction and separation processes, compositions, and
derivatives of Halloysite and other nanotubes. Visit www.naturalnano.com for more information.
About CellTraffix Inc.
CellTraffix
employs its unique understanding of the mechanics of cellular flow and cell
trafficking in the blood stream to develop a range of proprietary medical
devices. These are based on the CellSelect technology ranging from simple, low
cost research tools for the separation and collection of cells in blood, to
sophisticated in vivo and ex vivo therapeutic delivery systems and diagnostics
to address a number of unmet medical needs relating to cancer, adult stem cells
and immune cells. Visit www.celltraffix.com for more information.
Cautionary
Statement Regarding Forward-Looking Statements: This press release may contain
forward-looking statements regarding future events and future performance of
NaturalNano that involve risks and uncertainties that could materially affect
actual results. This information is qualified in its entirety by
cautionary statements and risk factors disclosure contained in certain of NaturalNano's
filings with the Securities and Exchange Commission. The most recent annual
reports on Form 10-KSB and quarterly reports on Form 10-QSB filed by
NaturalNano provide information about these factors, which may be revised or
supplemented in future reports to the SEC on those forms or on Form 8-K. We
caution investors not to place undue reliance on forward-looking statements,
and we do not undertake any obligation to update or otherwise revise any
forward-looking statements, whether as a result of new information, future
events, or other such factors that affect the subject of these statements,
except where expressly required by law.
# # #
Contact: NaturalNano,
Inc.
Jim Wemett
585-267-4848
This e-mail address is being protected from spam bots, you need JavaScript enabled to view it
|
